EVANSTON, Ill.—Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced earlier this summer the presentation of preclinical data on its novel NMDA receptor modulator, NYX-783, demonstrating that the product candidate robustly attenuated alcohol-seeking and relapse-like behavior in multiple models of alcohol use disorder.
Articles
Adjusting alcohol-seeking behavior
Aptinyx presents data demonstrating robust activity of NYX-783 in multiple modelsBrought to you byDDNews Staff
| 2 min read

To continue reading this article, subscribe for FREE to
Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.








